Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 5,756,578	$ 9,599,950
Short-term investments available-for-sale, at fair value	8,342,184	12,343,456
Accounts receivable, net of allowance of $20,315 at June 30, 2022 and December 31, 2021	1,259,093	2,092,466
Inventory, net	1,955,922	1,987,753
Prepaid expenses and other	2,011,072	1,163,339
Total current assets	19,324,849	27,186,964
Operating lease right-of-use assets	1,143,270	1,345,361
Property and equipment, net	780,695	1,118,886
Other non-current assets	956,655	809,476
Total assets	22,205,469	30,460,687
Current liabilities:
Accounts payable	1,119,452	1,649,440
Accrued liabilities	1,334,287	2,022,569
Current portion of long-term debt	6,614,817	5,167,586
NuvoGen obligation - current	523,849	548,301
Operating lease liabilities - current	429,200	413,865
Other current liabilities	137,644	141,749
Total current liabilities	10,159,249	9,943,510
NuvoGen obligation - non-current, net of discount	3,646,858	3,900,880
Long-term debt, net of current portion, discount and debt issuance costs	2,023,579	5,178,629
Other non-current liabilities	806,094	1,037,844
Total liabilities	16,635,780	20,060,863
Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; no shares authorized, issued and outstanding at June 30, 2022; 23,770 shares authorized, issued and outstanding at December 31, 2021		24
Common stock, $0.001 par value; 26,666,667 shares authorized at June 30, 2022 and December 31, 2021, 11,045,986 shares issued and outstanding at June 30, 2022 and 7,588,085 shares issued and outstanding at December 31, 2021	11,046	7,588
Additional paid-in-capital	226,293,112	218,723,349
Accumulated other comprehensive income (loss)	(15,710)	1,894
Accumulated deficit	(220,718,759)	(208,333,031)
Total stockholders’ equity	5,569,689	10,399,824
Total liabilities and stockholders' equity	$ 22,205,469	$ 30,460,687